DMWD Antikörper (Dystrophia Myotonica, WD Repeat Containing) (Cy5)

Details for Product anti-DMWD Antibody No. ABIN1704477
Antigen
  • D19S593E
  • DMR-N9
  • DMRN9
  • gene59
  • DMWD
  • Dm9
  • DM1 locus, WD repeat containing
  • dystrophia myotonica, WD repeat containing
  • dystrophia myotonica-containing WD repeat motif
  • DMWD
  • Dmwd
Reaktivität
Human, Maus, Ratte (Rattus)
43
20
20
4
4
4
3
1
1
Wirt
Kaninchen
39
4
Klonalität
Polyklonal
Konjugat
Dieser DMWD Antikörper ist konjugiert mit Cy5
3
3
3
2
2
2
1
1
1
1
1
1
1
1
1
1
Applikation
Immunofluorescence (Paraffin-embedded Sections) (IF (p))
31
22
12
5
2
2
Optionen
Immunogen KLH conjugated synthetic peptide derived from human DMWD/DMRN9
Isotyp IgG
Reinigung Purified by Protein A.
Plasmids, Primers & others Plasmide, Primers & weitere DMWD products on genomics-online (e.g. as negative or positive controls)
Antigen
Andere Bezeichnung Dmwd/Dmrn9 (DMWD Antibody Abstract)
Hintergrund

DMWD is a 674 amino acid protein containing five WD repeats. DMWD may play a role in the development of mental symptoms in severe cases of myotonic dystrophy, a chronic multisystemic disease characterized by wasting of the muscles, heart conduction defects, cataracts, endocrine changes and myotonia. The DMWD gene is located upstream of the DMPK gene and is prominently expressed in tissues affected in myotonic dystrophy patients. DMWD may also contribute to regulation in meiosis. DMWD is expressed in kidney and spleen, with strongest expression in brain, liver and testis. The gene encoding DMWD maps to human chromosome 19q13.32 and mouse chromosome 7 A3.

Synonyms: dystrophia myotonica containing WD repeat mot,D19S593E, DM 9, DM9, DMR N9, DMR N9 protein, DMRN 9, DMRN9, DMWD, DMWD_HUMAN, Dystrophia myotonica containing WD repeat mot, Dystrophia myotonica containing WD repeat mot protein, Dystrophia myotonica WD repeat containing protein, Dystrophia myotonica WD repeat-containing protein, Dystrophia myotonica-containing WD repeat mot protein, Gene59, Protein 59, Protein DMR-N9.

Gen-ID 1762
Applikations-hinweise IF(IHC-P) 1:50-200
Beschränkungen Nur für Forschungszwecke einsetzbar
Format Liquid
Konzentration 1 μg/μL
Buffer Aqueous buffered solution containing 1 % BSA, 50 % glycerol and 0.09 % sodium azide.
Konservierungs-mittel Sodium azide
Vorsichtsmaßnahmen This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Lagerung 4 °C
Informationen zur Lagerung Store at 4°C
Haltbarkeit 12 months
Haben Sie etwas anderes gesucht?